iTeos Therapeutics/ITOS

$10.79

-1.64%
-
1D1W1MYTD1YMAX

About iTeos Therapeutics

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. The Company’s pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, EOS-448, also known as GSK4428859A, is an antagonist of T-cell immunoreceptor with lg and ITIM domains, an immune checkpoint with multiple mechanisms of action. The Company is also advancing inupadenant, a next generation adenosine A2A receptor antagonist tailored to overcome the specific adenosine-mediated immunosuppression. It is investigating inupadenant in an open-label multi-arm Phase I/IIa clinical trial in adult cancer patients with advanced solid tumors.

Ticker

ITOS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michel Marcel Detheux

Employees

125

Headquarters

Watertown, United States

ITOS Metrics

BasicAdvanced
$386.12M
Market cap
-
P/E ratio
-$1.75
EPS
1.15
Beta
-
Dividend rate

What the Analysts think about ITOS

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
231.79% upside
High $47.00
Low $25.00
$10.79
Current price
$35.80
Average price target

ITOS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-32.2M
-6.12%
Profit margin
0%
-

ITOS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 25.21%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-
-$0.44
-$0.96
-$0.90
-
Expected
$0.33
-$0.99
-$1.03
-$1.20
-$1.03
Surprise
-
-55.75%
-6.8%
-25.21%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell iTeos Therapeutics stock

Buy or sell iTeos Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing